Website
News25/Ratings2
News · 26 weeks16+100%
2025-10-262026-04-19
Mix590d
- SEC Filings3(60%)
- Other2(40%)
Latest news
25 items- SECAmendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form NT 10-K filed by TherapeuticsMD Inc.NT 10-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form 10-K filed by TherapeuticsMD Inc.10-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces Full Year 2025 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.3) million, or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended Decemb
- INSIDERDirector Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form 10-Q filed by TherapeuticsMD Inc.10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces Third Quarter 2025 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third quarter of 2025, an increase of $237
- INSIDERSEC Form 4 filed by Director Thompson Tommy G4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- INSIDERSEC Form 4 filed by Director Naughton Gail K4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- INSIDERSEC Form 4 filed by Director Collins Cooper C.4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Walker Marlan D4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- SECSEC Form DEFA14A filed by TherapeuticsMD Inc.DEFA14A - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form DEF 14A filed by TherapeuticsMD Inc.DEF 14A - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form PRE 14A filed by TherapeuticsMD Inc.PRE 14A - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form 10-Q filed by TherapeuticsMD Inc.10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces Second Quarter 2025 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $545 thousand, or $0.05 per basic and diluted common share, compared to a net loss of $(1.05) million, or $(0.09) per basic and diluted common share, for the second quarter of 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.0 million for the second quarter of 2025, an increase of $0.
- SECSEC Form 10-Q filed by TherapeuticsMD Inc.10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECAmendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)
- INSIDERDirector Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- INSIDERChief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)4 - TherapeuticsMD, Inc. (0000025743) (Issuer)